The Multiple Sclerosis Therapy Market is on the Verge of an Overhaul – Video

Video Link: https://www.youtube.com/watch?v=4Y1Dp2t5nN8

19-06-2012 11:39 It's tragic to be sure, even if it takes a celebrity to bring the problem to light. Jack Osbourne - son of pop singer Ozzy Osbourne - was diagnosed with multiple sclerosis several days ago. As is likely the case with any newly-diagnosed MS sufferer, the question he soon began as king is, "Now what?" The answer was, though brave, also obvious... begin treatments, and fight. Unfortunately, Osbourne soon found out what the United States' 400000 multiple sclerosis patients (and the world's 2.5 million MS patients) already know too well... there is no cure, and treatment options aren't all that great either. That may not be the case for much longer, however. Though a true 'cure' isn't on the table yet, some treatments are proving to be effective, and a cure isn't out of the question.One of the more effective treatments us a drug called Fampyra, jointly made by Biogen Idec (NASDAQ:BIIB) and Acorda Therapeutics Inc. (NASDAQ:ACOR). Though the drug was approved for specific use - to improve casual walking in multiple sclerosis patients - in the United States a couple of years ago, it was only approved for the same use in Europe late last month. It's not been a bad drug, given that it's only approved to treat one specific MS-related ailment. Acorda Therapeutics booked $133 million in sales of Fampyra in the United States last year. Outside the US, Biogen Idec markets the drug and pays ACOR a royalty, so the new European permission should be a boost for both outfits

The rest is here:
The Multiple Sclerosis Therapy Market is on the Verge of an Overhaul - Video